TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06521554: A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

Sponsor: Nuvalent Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 200 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$376,992

Rescue Site Savings

+$251,328

Unlock Full NCT06521554 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06521554 Rescue Dossier →